Psychiatrically stable adults with schizophrenia were safely switched from their prior antipsychotic to the combination of xanomeline and trospium chloride, with no new safety issues uncovered, a 52‐week open‐label trial has found. The drug combination also led to improvements on measures of schizophrenia symptom severity. Results of the study were published online Jan. 7, 2026, in Schizophrenia Research .
A Wed, study studied this question.